Description
Co-Prenesa Tablets
Composition
Active ingredients: Perindopril tert-butylamine, Indapamide
Mechanism of Action
Co-Prenesa tablets combine the ACE inhibitor perindopril with the diuretic Indapamide to provide a dual mechanism of action in lowering blood pressure. Perindopril inhibits the angiotensin-converting enzyme, leading to vasodilation and reduced aldosterone secretion. Indapamide, a thiazide-like diuretic, promotes diuresis and vasodilation by inhibiting sodium reabsorption in the distal convoluted tubule.
Pharmacological Properties
The combination of perindopril and Indapamide in Co-Prenesa tablets results in effective blood pressure reduction through complementary mechanisms.
Indications for Use
Co-Prenesa tablets are indicated for the treatment of hypertension to lower blood pressure.
Contraindications
Avoid using Co-Prenesa tablets if you are allergic to any of the ingredients, have a history of angioedema related to previous ACE inhibitor therapy, or have severe renal impairment.
Side Effects
Common side effects may include dizziness, headache, or cough. Contact your healthcare provider if you experience any severe or persistent side effects.
Usage Instructions
Take one Co-Prenesa tablet daily, or as directed by a healthcare professional. Administer the tablet orally with a full glass of water, with or without food.
Benefits Compared to Analogues
Co-Prenesa tablets offer a dual-action approach to hypertension management, providing enhanced efficacy compared to single-agent therapies.
Suitable Patient Groups
Co-Prenesa tablets are suitable for adult patients with hypertension. Dosage adjustments may be necessary for elderly patients or those with renal impairment.
Storage and Shelf Life
Store Co-Prenesa tablets in a cool, dry place away from direct sunlight. Check the expiration date on the packaging and do not use expired tablets.
Packaging Description
Each package of Co-Prenesa contains 30 tablets of 8 mg perindopril tert-butylamine and 2.5 mg Indapamide.
Clinical Evidence and Proven Effectiveness
Clinical trials have demonstrated the efficacy of perindopril and Indapamide in reducing cardiovascular events and mortality in hypertensive patients. The ADVANCE study showed a significant risk reduction in major macrovascular or microvascular events with this combination therapy.
Additional Information
It is essential to monitor electrolytes and renal function periodically during treatment with Co-Prenesa tablets, particularly in patients with renal impairment or elderly patients. Avoid concurrent use of potassium-sparing diuretics, potassium supplements, or potassium-containing salt substitutes.
In conclusion, Co-Prenesa tablets offer a well-established combination therapy for hypertension with proven efficacy in reducing cardiovascular risk. Consult your healthcare provider for personalized recommendations and monitoring while using this medication.
